在全球爆发后,NanoViricides 在世卫组织的MEURI协议下探索对MPOX的NV-387治疗. NanoViricides explores NV-387 treatment for MPOX under WHO's MEURI protocol following a global outbreak.

一家临床阶段抗病毒纳米医学公司Nano Viricides正在探讨根据世卫组织的MEURI协议对MPOX(蒙基天花)病人进行NV-387治疗。 NanoViricides, a clinical-stage antiviral nanomedicines company, is exploring NV-387 treatment for MPOX (Monkeypox) patients under WHO's MEURI protocol. 这是继最近爆发疫情和卫生组织宣布国际关注公共卫生紧急事件之后发生的。 This follows the recent outbreak and WHO's declaration of a Public Health Emergency of International Concern. NV-387完成了第一阶段临床试验,在动物模型中,存活率有了显著改善,与Tecovirimat的功效相匹配。 NV-387 completed a Phase I clinical trial and demonstrated strong improvement in survival in an animal model, matching tecovirimat's effectiveness.